| Previous Close | Open | Close* |
|---|---|---|
| 269.06 | 268.51 | 269.23 |
| Market Cap | Dividend Yield (Annualized) |
|---|---|
| AUD 129.69B | 1.05% |
| Day Range |
|---|
| 268.27L 272.39 H |
| 52 WEEK HIGH LOW |
|---|
| 240.1L 319.78 H |
| Last Trade | 269.23 |
|---|---|
| Change% | 0.0632 |
| 52 W H/L | 319.780/240.100 |
| EBITDA | 3.519B |
| NPAT After Abnormal Items | 3.159B |
| Equity | 11.148B |
| ROE% | 29.46% |
| Total Liabilities | 13.003B |
| Total Revenue | 13.714B |
| Cash and Cash Equivalents | 2.406B |
| Share price | 269.23 |
|---|---|
| Market Cap | 129.69B |
| Price/Gross Cash Flow | 35.45 |
| Dividend Yield Excluding Special | 1.03% |
| Ending Shares | 455.126M |
| 52-Week Range | 319.780-240.100 |
| Gross DPS (AUD) | 3.0069 |
| Gross Dividend Yield (Annualized) | 1.05% |
| Earnings Yield | 2.740 |
| Net Tangible Asset (NTA) | 16.69 |
| P/E ratio | 36.496 |
| Sector P/E | -- |
| EPS | 693.00 |
| EV/EBITDA | 27.31 |
| Net Profit Margin (%) | 24.05% |
| Gross Cash Flows Per Share | 8.03 |
| Net Gearing | 47.70% |
| Sales Per Share | 29.95 |
| Book Value Per Share | 24.50 |
CSL Limited (ASX: CSL) is under the health care segment, and the company is engaged into development, research, manufacturing and marketing of cell culture media, human plasma fractions and pharmaceutical and diagnostic products. It is a biotherapeutics company and its segments include Seqirus, CSL Behring and CSL Intellectual Property. Other than Australia company has facilities in Switzerland, the United Kingdom and the United States. The company was incorporated in 1991 and is based in Poplar Road, Parkville, Australia.
| Ex-Date | Net Dividend | Frank Flag | Period End Date | Type | Payable |
|---|---|---|---|---|---|
| 02/09/2021 | $1.59 | 10% | 30/06/2021 | Final Dividend | 30/09/2021 |
| 19/09/2011 | $0.32 | 6% | 30/06/2011 | Final Dividend | 14/10/2011 |
| 13/09/2010 | $0.33 | 16% | 30/06/2010 | Final Dividend | 08/10/2010 |
| 17/09/2007 | $0.47 | 59% | 30/06/2007 | Final Dividend | 12/10/2007 |
| Event Type | Event Date | Event Year |
|---|---|---|
| Report (Interim) | 2023-02-15 | 2023 |
| Report (Annual) | 2022-09-02 | 2022 |
| Report (Prelim) | 2022-08-17 | 2022 |